Shanghai Allink Biotherapeutics Ltd. focus on the early discovery, clinical development and commercialization of bispecific antibody &bispecific antibody-drug conjugates (BsAb ADCs).
Location: China
Total raised: $89M
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.12.2025 | Series A | $47M | 5Y Capital |
| 02.12.2024 | Series A | $42M | - |
Mentions in press and media 6
| Date | Title | Description |
| 18.12.2025 | Allink Biotherapeutics Secures $47 Million, Propels Next-Gen Cancer and Immunology Therapies | Allink Biotherapeutics raised $47 million in Series A extension funding. This capital accelerates two critical antibody-drug conjugate (ADC) programs, ALK201 and ALK202, into global Phase I clinical trials. The biotech also expands its mult... |
| 16.12.2025 | Allink Biotherapeutics: $47 Million Series A Extension Raised To Advance Two ADC Programs And Expand Multispecific Platforms | Allink Biotherapeutics, a Shanghai-based clinical-stage biotechnology company developing antibody drug conjugates and multi-specific antibody therapeutics for oncology and immunology, has completed extension rounds of its Series A financing... |
| 16.12.2025 | BlackLine Acquires WiseLayer | BlackLine, Inc. (Nasdaq: BL), a Los Angeles, CA-based platform for CFOs, acquired WiseLayer, a New York-based company that has advanced a digital workforce of AI-powered agents to automate complex, judgment-based finance and accounting proc... |
| 16.12.2025 | Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development | The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly c... |
| 02.12.2024 | Allink Biotherapeutics: $42 Million (Series A) Raised To Transform Bispecific Antibody And Antibody-Drug Conjugate Therapeutics | Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific antibody and antibody-drug conjugate (ADC) therapeutics, announced the completion of a $42 million Series A financing. The funding round wa... |
| - | Allink Biotherapeutics | “Shanghai Allink Biotherapeutics Ltd. focus on the early discovery, clinical development and commercialization of bispecific antibody &bispecific antibody-drug conjugates (BsAb ADCs).” |